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The current outbreak of coronavirus disease (CO-VID-19), caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), continues 
to spread. As of June 27, 2020, the pandemic had 
affected 214 countries, resulting in 9,653,048 record-
ed cases and 491,128 deaths (1,2). Early detection of 
SARS-CoV-2 and immediate isolation of infected pa-
tients from the susceptible population is important 
for preventing the spread of infection (3). Real-time 
reverse transcription PCR (rRT-PCR) is currently the 
most reliable method for diagnosing COVID-19 (4).
Since March 2, 2020, the number of newly report-
ed cases in South Korea appears to be declining; the 
mean number of daily new confirmed cases decreased 
to 40 by the end of June (5). Intensive SARS-CoV-2 
testing helped to contain the spread of the disease in 
South Korea. Since March 1, South Korea (population 
≈51 million) has performed ≈20,000 tests per day by 
using rRT-PCR. The outstanding achievements of the 
public health response were attributable to the rapid 
expansion of diagnostic testing capabilities resulting 
from the collaboration between the public and private 
sectors. In June 2016, South Korea enacted emergency 
use authorization (EUA) legislation with the aim of 
supplying commercial kits to meet the demands of 
nongovernmental clinical laboratories and to guar-
antee quality assurance through mandatory technical 
training regarding standardized laboratory guide-
lines and external quality assessment (EQA) (6).
As of March 31, after successfully completing a 
proficiency testing panel consisting of 7-plasmid DNA 
specimens, a total of 95 nongovernmental clinical labo-
ratories were conducting SARS-CoV-2 tests by using 5 
different EUA kits (6). However, the nucleic acid extrac-
tion methods, rRT-PCR reagents, and thermocyclers 
used differed among laboratories. EQAs using pooled 
respiratory samples spiked with inactivated cultured 
SARS-CoV-2 had indicated the possible effects of these 
variations on assay performance, thereby allowing 
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External quality assessment (EQA) is essential for en-
suring reliable test results, especially when laboratories 
are using assays authorized for emergency use for newly 
emerging pathogens. We developed an EQA panel to as-
sess the quality of real-time reverse transcription PCR 
assays being used in South Korea to detect severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). With 
the participation of 23 public health organization labora-
tories and 95 nongovernmental laboratories involved in 
SARS-CoV-2 testing, we conducted qualitative and semi-
quantitative performance assessments by using pooled 
respiratory samples containing different viral loads of 
SARS-CoV-2 or human coronavirus OC43. A total of 
110 (93.2%) laboratories reported correct results for all 
qualitative tests; 29 (24.6%) laboratories had >1 outli-
ers according to cycle threshold values. Our EQA panel 
identified the potential weaknesses of currently available 
commercial reagent kits. The methodology we used can 
provide practical experience for those planning to con-
duct evaluations for testing of SARS-CoV-2 and other 
emerging pathogens in the future.
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the participating laboratories to assess the quality and 
identify the possible weaknesses and strengths of the 
currently used diagnostic methods (7,8). Therefore, we 
developed an EQA panel to assess the quality of SARS-
CoV-2 rRT-PCR assays in South Korea.
Methods
Participants
Because participation in the nationwide EQA request-
ed by the Korea Centers for Disease Control (KCDC) 
was mandatory for the 118 laboratories conducting 
SARS-CoV-2 tests, these laboratories were included 
in the our study by default. Because the study was 
a survey and an EQA that did not include personal 
identifiers or patient data, the requirement for institu-
tional review board approval was waived (waiver no. 
AMC IRB 2020-0547). The upper and lower respirato-
ry tract samples from SARS-CoV-2–negative patients 
were also included in the study.
Specimen Preparation
To construct the SARS-CoV-2 proficiency test panel, 
Vero cells (ATCC CCL-81, American Type Culture 
Collection, https://www.atcc.org) were inoculated 
with the SARS-CoV-2 KNIH001 strain (from KCDC) 
and cultured at 37°C at 5% CO2 for 5 days (9). Infection 
was confirmed by assessing the cytopathic effects and 
by rRT-PCR assays using primers and probe sets de-
scribed previously by Corman et al. (10). The titer was 
1.0 × 106 PFU/mL, and the cycle threshold (Ct) value 
of the SARS-CoV-2 E gene was ≈16. The virus was in-
activated at 70°C for 1 hour. No infectious virus was 
detected on testing for residual infectivity after heat 
treatment by inoculation in cell culture. Dilution matri-
ces were established by using pooled nasopharyngeal 
aspirates, to represent upper respiratory tract samples, 
and pooled sputum or bronchoalveolar lavage flu-
ids, to represent lower respiratory tract samples. All 
pooled samples were negative for common respiratory 
viruses and SARS-CoV-2. Liquillizer (MetaSystems, 
https://metasystems-international.com) was added to 
the pooled lower respiratory tract samples for dilution 
to achieve a final concentration of 10%.
The proficiency test panel included 4 each of up-
per and lower respiratory tract samples containing 
serial 10-fold dilutions of SARS-CoV-2–positive cell 
culture supernatant (1:2 × 102-1:2 × 105), 1 human 
coronavirus OC43 (HCoV-OC43)–positive/SARS-
CoV-2–negative upper respiratory tract sample, and 1 
negative lower respiratory tract sample. The samples 
were immediately frozen at -70°C after aliquoting. 
Although participants were informed that the 
materials were nonbiohazardous, we recommended 
that they be handled according to general basic re-
quirements regarding human specimens.
Validation and Dispatch of Panel Tests and Collection 
of EQA Results
To validate stability and homogeneity, EQA panel 
samples were assayed by 3 extraction systems, 4 EUA 
reagents, and 2 thermocyclers. For assessing homoge-
neity, 3 panels were selected at random and assayed 
in triplicates, generating 9 test results; for stability, 
samples were maintained at -70°C for 1 day, 3 days, 
and 7 days. Three panels from each storage condition 
were then selected at random and assayed 3 times. 
EQA samples were shipped on dry ice with tem-
perature monitoring by Green Cross Labcell (http://
www.gclabcell.co.kr). Delivery to all laboratories, in-
cluding those on Jeju Island, was completed within 
10 hours. The Korean Association of External Qual-
ity Assessment Service (KEQAS) was responsible for 
the transport of the EQA material, collection of the 
EQA results, and evaluation of results. All EQA data, 
including those of test sample volumes, extraction re-
agents and instruments, and elution volumes, were 
submitted through the KEQAS program web site 
(http://eqas.keqas.org).
Evaluating the EQA Results and Statistical Analysis
For qualitative evaluations, only samples with an 
>80% agreement rate compared with the expected 
results were evaluated (11). All EUA kits included 
the manufacturer’s instructions for threshold set-
tings or use of an exclusive interpretation–viewer 
program from the manufacturer. For evaluations of 
semiquantitative data, the mean, median, and inter-
quartile ranges of the Ct values were converted to 
box-and-whisker plots. Outliers were defined when 
determined by a double-sided Grubbs test, when 
a negative result for positive sample was given, or 
when any Ct value in negative samples was report-
ed. The outlier frequencies were compared by using 
the χ2 test. The likelihood ratios for different tests 
were calculated from a 2 × k table. For homogeneity 
and stability tests, the mean value and percentage 
coefficient of variation (%CV) of the 9 results from 
triplicated assays of 3 samples were analyzed, and 
assumption of homogeneity of variance was tested 
by using Levine’s test of equality of variances. Ho-
mogeneity and stability were satisfactory when the 
%CV was <5 and p value was >0.05. MedCalc Statis-
tical Software version 19.2.1 (MedCalc Software Ltd, 
https://www.medcalc.org) was used for all statisti-
cal analyses.
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Results
Participating Laboratories
Twenty-three public laboratories conducting COV-
ID-19 tests, including 18 regional Institutes of Health 
and Environment, 4 National Quarantine Stations, 
and 1 Armed Force Medical Science Research Insti-
tute, participated, along with 95 nongovernmental 
clinical laboratories. Sixty-six (55.9%) laboratories 
were located in the Seoul, Incheon, and Gyeonggi 
metropolitan areas, in which 49.6% of the total popu-
lation of South Korea resides.
SARS-CoV-2 Testing Protocols
Protocols for SARS-CoV-2 rRT-PCR varied among the 
118 participating laboratories (Figure 1). Ninety-five 
nongovernmental clinical laboratories were allowed to 
use only 1 of the 5 EUA rRT-PCR reagents. Five regional 
Institutes of Health and Environment used laboratory-
developed tests using the primers and probes described 
by Corman et al. (10) and AgPath-ID 1-step RT-PCR 
reagents (ThermoFisher Scientific, https://www.ther-
mofisher.com). A large variance in extraction steps, re-
agents, instruments, sample volumes, and elution vol-
umes (i.e., sample volume equivalent RNA input) was 
observed (Figures 1, 2). For SARS-CoV-2 detection, 67 
laboratories (56.8%) used the PowerChek 2019-nCoV 
Kit (Kogene Biotech, http://www.kogene.co.kr), which 
was the first EUA SARS-CoV-2 assay cleared by KCDC 
and the Korea Food and Drug Administration, and 38 
laboratories (32.2%) used the Allplex 2019-nCoV Kit 
(Seegene, http://www.seegene.com).
Qualitative rRT-PCR Results
Because the lower respiratory tract sample with the 
highest dilution (nCoV-2041) showed 78.8% (93/118) 
agreement compared with the expected results, lower 
respiratory tract sample results were excluded from 
the final analysis. A total of 110 laboratories (93.2%) 
reported correct results for all qualitative tests.
Among the 38 laboratories using the Allplex 
2019-nCoV Kit (Seegene), 8 (21.1%) laboratories had 
>1 incorrect results, in which all incorrect results 
were reported from lower respiratory tract samples 
(nCoV-20–41, -42, -43, or -45) (Appendix Table 1, 
https://wwwnc.cdc.gov/EID/article/26/10/20-
2551-App1.pdf). Eighty laboratories using the other 
EUA kits or WHO primers and probes provided 
correct results for all evaluable results. The likeli-
hood ratio of unacceptable results from the All-
plex 2019-nCoV Kit compared with the other kits 
was 0.273 (95% CI 0.201-0.370). Other kits 95% CIs 
of likelihood ratios included 1.000. Extraction re-
agent kits used by laboratories that reported in-
correct results were STARMag DNA/RNA Ex-
traction Kit (Seegene) and NucliSENS easyMAG 
Figure 1. Protocols used for real-time RT-PCR in 118 laboratories participating in an external quality assessment of severe acute 
respiratory syndrome coronavirus 2 testing, South Korea, March 23–27, 2020. The flow diagram shows the variations in specimens 
tested, RNA extraction platforms, PCR reagents and amplification platforms, and sample volume equivalent RNA input used in the PCR 
reaction. The weight of the lines reflects the number of laboratories using a particular step. Numbers in the circles indicate number of 
laboratories. RT-PCR, reverse transcription PCR.
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Extraction Kit (bioMérieux, https://www.biom-
erieux.com) used by 3 laboratories. The other 2 
laboratories used Advansure R Extraction Kit 
(LG Chem, https://www.lgchem.com) or Exiprep 
Plus Viral DNA/RNA Extraction Kit (Bioneer, 
https://eng.bioneer.com).
Semiquantitative Results by Ct value
The Ct values of the SARS-CoV-2 RdRp gene for each 
EUA assay, except for the DiaPlexQ 2019-nCoV kit 
(Solgent, http://www.solgent.com), which detects 
the ORF1a and N genes, and expected Ct value for 
each sample for PowerChek 2019-nCoV and Allplex 
2019-nCoV are shown in Table 1. E gene and RdRp 
gene Ct values from 67 laboratories using the Pow-
erChek 2019-nCoV reagents and E gene, RdRp gene, 
and N gene Ct values from 38 laboratories using the 
Allplex 2019-nCoV reagents are shown in Figure 3.
For extraction kits, all 13 laboratories using the 
STARMag DNA/RNA extraction kit had >1 outlier 
Figure 2. Protocols used for laboratories that reported >1 outliers in results of real-time RT-PCR tests for severe acute respiratory 
syndrome coronavirus 2, South Korea, March 23–27, 2020. The flow diagram shows the variations in specimens tested, RNA extraction 
platforms, PCR reagents and amplification platforms, and sample volume equivalent RNA input used in the PCR reaction. The weight 
of the lines reflects the number of laboratories using a particular step. Numbers in the circles indicate number of laboratories. RT-PCR, 
reverse transcription PCR.
 
Table 1. Test results for severe acute respiratory syndrome coronavirus 2 RdRp gene obtained from the proficiency test provider 







Standard M, N = 6 
Laboratory-
developed test,  
N = 5 
Real-
Q,  










N = 38† 
41 1:2 × 105 33.60 33.64 + 1.73  34.37 34.64 + 2.23‡ 30.38 (29.44–35.46)§ 34.32 (32.57–34.62) 38.27 
42 1:2 × 102 24.62 24.16 + 1.68  25.67 26.29 + 2.34 21.28 (19.98–27.54) 25.94 (23.28–28.07) 24.06 
43 1:2 × 104 30.73 30.60 + 1.45  31.34 32.05 + 2.43¶ 27.49 (26.79–33.39) 31.66 (30.01–32.83) 30.54 
45 1:2 × 103 27.69 27.71 + 1.66  28.73 29.40 + 2.51# 24.67 (23.51–31·21) 28.12 (26.77–29.05) 27.31 
46 1:2 × 103 24.82 25.61 + 0.76  26.12 26.07 + 1.11 22.18 (21.50–23.46) 27.78 (25.74–28.49) 26.61 
48 1:2 × 102 21.27 22.06 + 0.85  22.49 22.41 + 1.06 19.06 (17.20–19.86) 24.07 (22.04–25.02) 22.96 
49 1:2 × 105 32.14 32.57 + 0.96  32.55 32.35 + 1.13 29.36 (27.49–30.02) 34.39 (32.18–35.42) 33.36 
50 1:2 × 104 28.58 29.19 + 0.83  29.45 29.32 + 1.10 25.82 (24.20–27.01) 31.29 (29.38–32.40) 29.21 
*Cycle threshold values are shown. Mean + SD is shown for the results obtained by using the PowerChek 2019-nCoV and Allplex 2019-nCoV kits. 
Median and range are shown for the results obtained by using the Standard M nCoV-Detection and laboratory-developed tests. 
†For nCoV-20–41−45, the number of laboratories was 37. 
‡Calculated after exclusion of negative results from 9 laboratories. 
§Calculated after exclusion of negative results from 1 laboratory. 
¶Calculated after exclusion of negative results from 3 laboratories. 
#Calculated after exclusion of negative results from 1 laboratory. 
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results (Figure 2). The likelihood ratio of outliers from 
the STARMag DNA/RNA kit compared with the oth-
er kits was 0.000 (95% CI 0.000-0.205). Other extrac-
tion kits 95% CIs of likelihood ratios included 1.000.
Among the laboratories using the PowerCheck 
2019-nCoV kit, five (0.7%, 5/670) outliers occurred in 
the E gene Ct values at 5 (7.5%) laboratories. Three 
(0.4%, 3/670) outliers occurred in the RdRp gene Ct 
values from 2 (3.0%) laboratories (Appendix Table 2).
Among the laboratories using the Allplex 2019-
nCoV kit, 37 (9.9%) outliers occurred in E gene results, 
13 (3.5%) in RdRp gene results, and 5 (1.3%) in N gene 
results (Appendix Table 2). The frequency of total 
outliers for the Allplex 2019-nCoV kit was significant-
ly higher than those for the PowerChek 2019-nCoV 
kit (4.9% vs. 0.6%; p<0.0001). Except for 2 outliers for 
the E gene, all other outliers were negative results for 
lower respiratory samples that should have been pos-
itive. Among the laboratories using the Standard M 
nCoV Real-Time Detection kit (SD Biosensor, http://
www.sdbiosensor.com), 2 laboratories (33.3%) that 
used the STARMag extraction kit reported negative 
results for the nCoV-20–41 sample.
Variation by Extraction Method and rRT-PCR  
Reagent of EQA samples
For the Standard M nCoV Real-Time Detection kit, 
the E gene Ct value was lower, by ≈2.8, than that of 
the Allplex nCoV-2019 kit and lower, by ≈3.9, than 
that of the PowerChek nCoV-2019 kit. For the Real-
Q viral RNA extraction kit, the E gene Ct value was 
lower, by ≈1.4, than that of the NucliSENS easyMAG 
Figure 3. Semiquantitative real-time reverse transcription PCR 
Ct values for severe acute respiratory syndrome coronavirus 
2 proficiency panel samples tested by PowerChek and Allplex 
2019-nCoV kits, South Korea, March 23–27, 2020. Horizontal 
line within each box denotes the median value; x indicates the 
mean; top and bottom of box indicate third and first quartiles, 
respectively; error bars indicate minimum and maximum values; 
dots indicate outlier results. E gene (A) and RdRp gene (B) Ct 
values were from 67 laboratories using the PowerChek 2019-
nCoV reagents; E gene (C), RdRp gene (D), and N gene (E) Ct 
values were from 38 laboratories using the Allplex 2019-nCoV 
reagents. Ct, cycle threshold.
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extraction kit. For the STARMag DNA/RNA extrac-
tion kit, 1 negative result occurred for the nCoV-20–
41 E gene. However, the results were positive for the 
RdRp and N genes using the Allplex nCoV-2019 kit.
Homogeneity and Stability of EQA Samples
For homogeneity tests, the mean Ct value and %CV 
of each target gene using the NucliSENS easyMAG 
kit for extraction and the Allplex nCoV-2019 kit for 
amplification are shown in Table 2. All the Ct values 
were within acceptable ranges, with %CVs <5. For 
stability tests, Ct values obtained for the SARS-CoV-2 
EQA panel were also within acceptable ranges, with 
%CVs <5 (data not shown).
Discussion
The most important element for reducing the trans-
mission of SARS-CoV-2 is the early detection of SARS-
CoV-2 in patients. Shortening the time to diagnosis 
could substantially reduce the risk for transmission 
of SARS-CoV-2 (12). Performing diagnostic tests for 
newly emerging pathogens, such as SARS-CoV-2, ex-
clusively in governmental and public laboratories sub-
stantially increases the delay resulting from logistics 
and analytical processes. As a result, diagnosis and iso-
lation of patients, contact tracing, and even treatment 
of symptomatic patients can be delayed. Thus, rapid 
extension of diagnostic testing for emerging pathogens 
to nongovernmental clinical laboratories has many 
advantages, such as shorter turnaround times (13). 
To ensure reliable test results, EQA is a fundamen-
tal element, especially when using EUA diagnostic 
kits for newly emerging pathogens (8,14). The EQA 
we describe is unique because of its nationwide scale 
and because it included public and nongovernmental 
clinical laboratories conducting SARS-CoV-2 testing. 
This EQA was well-timed to support the laboratory re-
sponses to minimize the ongoing outbreak. All public 
and nongovernmental laboratories conducting SARS-
CoV-2 molecular diagnostics reported their results in 
this nationwide EQA assessment in South Korea. The 
performance of the participants was good; overall ac-
curacy was 100% for upper respiratory tract samples 
and 93.2% for lower respiratory tract samples.
On the basis of the laboratory results, the nCoV-
20–41 sample was omitted from qualitative analysis. 
Initially, cultured SARS-CoV-2 were heat-inactivated 
at 65°C for 30 minutes (15). However, the second pas-
sage of cell cultures with inactivated viruses showed 
equivocal cytopathic effects, and therefore, the cul-
tured viruses were further heat-inactivated at 70°C 
for 1 hour. The relatively high temperature and pro-
longed heat inactivation might have caused viral cap-
sid denaturation and release of RNA. Viral RNA in the 
lower respiratory samples are vulnerable to degrada-
tion by RNase because of the lack of preservatives, 
in contrast to that observed in the universal transport 
medium used for upper respiratory tract samples. Ct 
values of the lower respiratory tract samples might 
have been higher than those of the upper respiratory 
tract samples, despite aliquoting the same amount of 
virus. Including replicate samples using the same ma-
trix for assessing test consistency is preferred.
Among 118 public and nongovernment clinical 
laboratories, 8 (6.8%) laboratories using the Allplex 
2019-nCoV kit reported >1 incorrect results for lower 
respiratory tract samples in the qualitative assess-
ment. Whether this finding was attributable to the 
matrix effects of the proficiency test samples or the 
decreased sensitivity of the Allplex 2019-nCoV kit is 
unclear. Because the Liquillizer mucolytic agent was 
added to the inactivated virus-spiked lower respira-
tory tract samples, it could have adversely affected 
the extraction or the amplification procedures, al-
though no interference with molecular methods has 
been observed by the manufacturer (16). Laboratories 
that had incorrect results on their qualitative tests 
were asked to take corrective actions by reevaluating 
 
Table 2. Severe acute respiratory syndrome coronavirus 2 external quality assessment panel homogeneity tests of triplicate test 
results of 3 samples using the NucliSENS easyMAG extraction and Allplex nCoV-2019 kits performed at the Asan Medical Center, 







Mean Ct %CV Mean Ct %CV Mean Ct %CV 
41 33.82 4.5  34.37 1.6  34.38 0.5 
42 25.15 1.4  25.67 1.8  26.67 0.5 
43 30.33 1.5  31.34 1.5  31.55 0.7 
44 ND ND  ND ND  ND ND 
45 27.52 2.2  28.73 0.3  29.05 0.7 
46 24.47 0.7  26.12 0.3  27.05 0.2 
47 ND ND  ND ND  ND ND 
48 20.68 2.5  22.49 0.6  23.49 0.3 
49 31.07 0.8  32.55 0.6  33.32 0.9 
50 27.89 0.9  29.45 0.2  30.35 0.6 
*Ct, cycle threshold; EQA, external quality assessment; %CV, percentage coefficient of variation; ND, not detected. 
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their nucleic acid extraction protocols and internal 
quality control processes according to the laboratory 
guidelines (4,17) and implementing the routine use of 
a commercial reference material. A follow-up EQA 
consisting of 5 samples was conducted a month later, 
and clinical laboratories participated in a follow-up 
EQA showed all acceptable results.
For the assessment of semiquantitative data, only 
0.6% outlier results were obtained by 67 laboratories 
using the PowerChek 2019-nCoV kit. In contrast, 
4.9% outlier results were reported from 38 laborato-
ries using the Allplex nCoV 2019-nCoV kit. For the 
PowerChek 2019-nCoV kit, which uses 2 PCR tubes, 2 
separate tubes for both the E and RdRp genes are nec-
essary per sample, and the volume of RNA is 5 μL per 
reaction tube (4,17). For the Allplex 2019-nCoV kit, the 
internal control is directly added into the sample, and 
the volume of RNA is 8 μL. The target genes are the 
E, RdRp, and N genes. The manufacturers’ reported 
limit of detection for the E gene is 28.5 copies/reac-
tion for the PowerChek 2019-nCoV kit and 100 cop-
ies/reaction for the Allplex 2019-nCoV kit. Whether 
the lower limit of detection and decreased multiplex-
ing (each gene and an internal control per tube for 
the PowerChek 2019-nCoV kit vs. 3 target genes and 
an internal control per tube for the Allplex 2019-
nCoV kit) affected the performance of the 2 reagents 
or whether matrix effects occurred during use of the 
Allplex 2019-nCoV kit requires further investigation.
The first step in nucleic acid amplification tests 
requires extraction and purification of nucleic acids 
from the target organism (18). All 13 laboratories us-
ing the STARMag DNA/RNA extraction kit report-
ed >1 outliers. During the preevaluation of the ex-
traction systems and EUA rRT-PCR assays that were 
performed in the central laboratory before dispatch, 
a combination of STARMag DNA/RNA extraction 
and Allplex 2019-nCoV kits showed a negative result 
for the E gene in the nCoV-20–41 specimen, which 
had the lowest viral load. Specimen viscosity and 
higher rates of PCR inhibition account for sputum 
being the most difficult specimen type to analyze in 
the laboratory (19). Although the manufacturer of the 
STARMag DNA/RNA extraction kit claims that spu-
tum and bronchoalveolar lavage are suitable types 
of specimens, laboratories should verify these claims 
and assess the performance of nucleic acid amplifi-
cation tests when using this reagent for extracting 
RNA from lower respiratory tract samples. The labo-
ratories given incorrect qualitative results were re-
quested to compare their nucleic acid extraction sys-
tem with the QIAamp Viral RNA Mini kit (QIAGEN, 
https://www.qiagen.com) (17).
All EQA samples were adequately homogeneous 
and stable on storage at -70°C. Because the complete 
process of this EQA, from proficiency test panel prep-
aration, panel freezing, and logistics to completion 
of testing and result reporting, was finished within 
a week, the assessment was conducted in 7 days. The 
reliability of the virus panels used in the EQA was 
found to be stable.
Our study has some limitations. First is the small 
number of negative SARS-CoV-2 samples to evalu-
ate cross-contamination, including only 2 negative 
samples. More negative samples placed adjacent to 
the highest SARS-CoV-2 sample should be included 
in future EQA for the evaluation of cross-contamina-
tion. Second, the potential matrix effect of the addi-
tives to the lower respiratory tract samples was not 
evaluated properly. Thus, for the laboratories using 
the Allplex 2019-nCoV kit, the performance of the 
reagent when using lower respiratory tract samples 
might not have been assessed adequately. Because 
variations occurred in the tested specimen types, 
RNA extraction platforms, PCR reagents and amplifi-
cation platforms, and the amount of RNA used in the 
PCR reaction, many potential variables could have af-
fected the results. Third is the small volume of EQA 
samples. A sufficient amount of sample for certifi-
cation of multiplex technicians is recommended for 
certain EQA exercises; however, EQA samples were 
enough for ≈4 test runs when using a QIAamp Viral 
RNA Mini kit. Fourth, the EQA panel had limitations 
regarding test consistency evaluation; measured val-
ues varied between sample types because of a poten-
tial matrix effect, despite having the same viral loads 
from both upper and lower respiratory samples. An 
international EQA that includes replicate samples for 
consistency evaluation is ongoing, and the laborato-
ries conducting SARS-CoV-2 testing are highly en-
couraged to participate in that program.
In conclusion, this report summarizes the nation-
wide EQA of SARS-CoV-2 molecular testing carried 
out by public and nongovernmental laboratories. 
The observation that 6.8% of laboratories reported 
false-negative results shows room for improvement. 
Laboratories with deficiencies were requested to take 
additional corrective actions and then participated 
in a follow-up EQA. This study indicates that EQAs 
should be performed for all laboratories involved in 
COVID-19 diagnostic testing on a regular basis for 
evaluation of potential weaknesses in SARS-CoV-2 
molecular testing procedures. This action will help 
to increase the quality of results. The EQA methodol-
ogy used in this study will also help other countries 
to evaluate their own assays for SARS-CoV-2 testing.
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